Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...
On June 28, 2012, the most significant scientific breakthrough of the first quarter of the 21st century was announced to the ...
BRENTFORD, ENGLAND, UNITED KINGDOM, October 14, 2025 / EINPresswire.com / -- The global CRISPR gene-editing market is expected to witness significant growth, projected to rise from a valuation of US$ ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...
27d
Gene editing is being sold on the promise of healthier babies — but what are the ethical concerns?
The race to advance gene editing tech continues, spurred on by starry-eyed Silicon Valley investors, entrepreneurs and even ...
Any banana you eat today is probably a clone. You may have noticed it doesn’t have seeds. And that’s because nearly every ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback